# Delphia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/delphia-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.delphiatx.com
- Total disclosed funding: $67M
- Latest round: Series A (May 3, 2024)
- Investors on record: 4

## About

Founded in 2022 and based in Massachusetts, US, Delphia Therapeutics, Inc. operates as a biotechnology company that develops therapeutics for cancer treatment. In May 2024, Delphia Therapeutics, Inc. raised USD 67 million in Series A funding co-led by investors GV, Nextech, Polaris, and Alexandria Venture Investments.

The firm offers therapies that charge activation lethality, that exploits cancer's vulnerability to oncogene overactivation to provide cancer treatment. The firm offers therapies and novel medicines that address the challenge of drug resistance commonly seen with traditional targeted therapies. 

The company intends to use the May 2024 funding to expand its market reach and improve research and development efforts.

## Funding rounds

- Series A, May 3, 2024, $67M — Alexandria Venture Investments, Nextech, GV, Polaris

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A
- Polaris (https://capitalatlas.ai/funds/polaris) — Series A